{"id":568008,"date":"2021-10-08T18:30:01","date_gmt":"2021-10-08T18:30:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=568008"},"modified":"2021-10-08T18:30:01","modified_gmt":"2021-10-08T18:30:01","slug":"the-market-size-of-persistent-corneal-epithelial-defects-is-anticipated-to-increase-during-the-study-period-201830-in-the-7mm","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/the-market-size-of-persistent-corneal-epithelial-defects-is-anticipated-to-increase-during-the-study-period-201830-in-the-7mm_568008.html","title":{"rendered":"The market size of Persistent Corneal Epithelial Defects is anticipated to increase during the study period (2018-30) in the 7MM"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1633666382.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"The market size of Persistent Corneal Epithelial Defects is anticipated to increase during the study period (2018-30) in the 7MM\" src=\"https:\/\/www.abnewswire.com\/uploads\/1633666382.png\" alt=\"The market size of Persistent Corneal Epithelial Defects is anticipated to increase during the study period (2018-30) in the 7MM\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Persistent Corneal Epithelial Defects Market <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The total PCEDs market size of PCED includes the market size of both the potential upcoming therapies such as Nexagon, ST266, and others, along with the current treatment modalities in the 7MM.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/8a70c5e57eb5c279911dc323c32e4a7f.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/persistent-epithelial-defect-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Persistent Corneal Epithelial Defects market report<\/a><\/strong> offers detailed information on current treatment practices, emerging drugs, Persistent Corneal Epithelial Defects market share of the individual therapies, current and forecasted Persistent Corneal Epithelial Defects market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Spain, Germany, Italy, and France), and Japan).&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the Key Highlights from the Persistent Corneal Epithelial Defects Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">As per DelveInsight estimates, the total Persistent Corneal Epithelial Defects incidents cases was <strong>241,452<\/strong> in the 7MM in 2020.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Among the EU5 countries, <strong>Germany<\/strong> had the highest PCEDs incident cases in 2020.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Leading companies such as <strong>OcuNexus Therapeutics, Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals,<\/strong> and others are developing novel therapies for Persistent Corneal Epithelial Defects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key PCEDs pipeline therapies expected to launch in the upcoming years include <strong>Nexagon, ST266, RGN-259,<\/strong> and others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Nexagon (OcuNexus Therapeutics\/Eyevance Pharmaceuticals)<\/strong> has received Orphan Drug Designation from the FDA. It is currently in the Phase II studies for PEDs<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>RGN-259<\/strong> is a sterile and preservative-free eye drop based on Thymosin beta-4 (T4) developed as a novel treatment by <strong>RegeneRx Biopharmaceuticals.<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">Request for PCEDs market report sample to understand more about the emerging drug landscape @<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/persistent-epithelial-defect-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\"> Persistent Corneal Epithelial Defects Treatment Market Analysis<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Persistent Corneal Epithelial Defects: Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Persistent Corneal Epithelial Defects (PEDs or PCEDs) are caused by the failure of rapid re-epithelialization and closure following a corneal injury within 10-14 days, even with standard supportive treatment. PED awareness has grown in recent years due to increased research activities across the spectrum of ophthalmology research.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Persistent Corneal Epithelial Defects Epidemiology Segmentation<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Persistent Corneal Epithelial Defects report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Persistent Corneal Epithelial Defects Incident Cases<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Persistent Corneal Epithelial Defects Gender-Based Incident Cases<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Persistent Corneal Epithelial Defects Etiology-Specific Incidence<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Persistent Corneal Epithelial Defects Therapeutics Market<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The current PCEDs treatment approaches include <strong>Aggressive Lubrication, Punctal Occlusion, Bandage Soft Contact Lens, Pressure Patching, Tetracyclines, Prophylactic Topical Antibiotics, and Steroids.<\/strong> Whereas, <strong>Amniotic Membrane Grafting, Autologous Serum, Scleral Contact Lenses,<\/strong> and other treatments are used to treat refractory cases.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Persistent Corneal Epithelial Defects Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The total PCEDs market size of PCED includes the market size of both the potential upcoming therapies such as <strong>Nexagon, ST266, RGN-259,<\/strong> and others, along with the current treatment modalities in the 7MM.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Discover more about the future market share of the drugs @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/persistent-epithelial-defect-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Persistent Corneal Epithelial Defects Market Share<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Persistent Corneal Epithelial Defects Pipeline Therapies and Key Companies<\/strong>&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Nexagon: OcuNexus Therapeutics\/ Eyevance Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">ST266: Noveome Biotherapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">RGN-259: RegeneRx Biopharmaceuticals<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Persistent Corneal Epithelial Defects Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Increasing R&amp;D activities<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Emerging PCEDs Pipeline<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Available Standard Therapies<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Persistent Corneal Epithelial Defects Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Lack of approved Therapies in the market<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Challenges in Drug Delivery<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Lack of Animal models<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope for the Report<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Coverage:<\/strong> 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Study Period:<\/strong> 2018-30<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Persistent Corneal Epithelial Defects Key Companies:<\/strong> OcuNexus Therapeutics, Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, among others.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Persistent Corneal Epithelial Defects Key Pipeline Therapies:<\/strong> Nexagon, ST266, RGN-259, and others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Persistent Corneal Epithelial Defects Segmentation:<\/strong> By Geography, By Persistent Corneal Epithelial Defects therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analysis:<\/strong> Comparative and conjoint analysis of Persistent Corneal Epithelial Defects emerging therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Tools Used:<\/strong> SWOT Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Case Studies<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>KOL&rsquo;s Views<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analyst&rsquo;s Views<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"85\" \/>\n<col width=\"539\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\">1.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Key Insights<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">2.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Report Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">3.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Persistent Corneal Epithelial Defects Market Overview at a Glance<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">4.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Executive Summary of Persistent Corneal Epithelial Defects<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">5.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Organizations contributing towards Persistent Epithelial Defect (PED)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">6.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Persistent Corneal Epithelial Defects Disease Background and Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">7.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Persistent Corneal Epithelial Defects Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">8.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Persistent Corneal Epithelial Defects Epidemiology and Patient Population<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">9.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Persistent Corneal Epithelial Defects Current Treatment Practices<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">10.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Patient Journey<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">11.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Case Report<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">12.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Persistent Corneal Epithelial Defects Marketed Therapies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">13.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Persistent Corneal Epithelial Defects Emerging Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">14.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Persistent Corneal Epithelial Defects: 7 Major Market Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">15.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Persistent Corneal Epithelial Defects Market Outlook<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">16.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Persistent Corneal Epithelial Defects Market Drivers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">17.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Persistent Corneal Epithelial Defects Market Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">18.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">KOL Views<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">19.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">SWOT Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">20.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">21.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Report Methodology<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">22.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">DelveInsight Capabilities<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">23.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Disclaimer<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">24.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">For rich insights into Healthcare and Pharmaceutical News, visit <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Pharma, Healthcare, and Biotech Blog Posts<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/corneal-endothelial-dystrophy-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Corneal Endothelial Dystrophy Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Get a comprehensive analysis of Corneal Endothelial Dystrophy pipeline therapies and key companies such as <strong>Aerie Pharmaceuticals, Kowa Pharmaceuticals, Trefoil Therapeutics,<\/strong> among others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=the-market-size-of-persistent-corneal-epithelial-defects-is-anticipated-to-increase-during-the-study-period-201830-in-the-7mm\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=the-market-size-of-persistent-corneal-epithelial-defects-is-anticipated-to-increase-during-the-study-period-201830-in-the-7mm\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Persistent Corneal Epithelial Defects Market The total PCEDs market size of PCED includes the market size of both the potential upcoming therapies such as Nexagon, ST266, and others, along with the current treatment modalities in the 7MM. DelveInsight&rsquo;s Persistent Corneal &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/the-market-size-of-persistent-corneal-epithelial-defects-is-anticipated-to-increase-during-the-study-period-201830-in-the-7mm_568008.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,420,403,404],"tags":[],"class_list":["post-568008","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/568008","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=568008"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/568008\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=568008"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=568008"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=568008"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}